Correlation Between MedinCell and Apellis Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both MedinCell and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MedinCell and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between MedinCell SA and Apellis Pharmaceuticals, you can compare the effects of market volatilities on MedinCell and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MedinCell with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of MedinCell and Apellis Pharmaceuticals.

Diversification Opportunities for MedinCell and Apellis Pharmaceuticals

0.0

Correlation Coefficient

MedinCell  Apellis Pharmaceuticals

Pay attention - limited upside

The 3 months correlation between MedinCell and Apellis is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding MedinCell SA and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and MedinCell is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MedinCell SA are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of MedinCell i.e., MedinCell and Apellis Pharmaceuticals go up and down completely randomly.

Pair Corralation between MedinCell and Apellis Pharmaceuticals

Assuming the 90 days horizon MedinCell SA is expected to under-perform the Apellis Pharmaceuticals. But the pink sheet apears to be less risky and, when comparing its historical volatility, MedinCell SA is 2.67 times less risky than Apellis Pharmaceuticals. The pink sheet trades about -0.03 of its potential returns per unit of risk. The Apellis Pharmaceuticals is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  4,756  in Apellis Pharmaceuticals on September 26, 2024 and sell it today you would lose (1,424) from holding Apellis Pharmaceuticals or give up 29.94% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	99.8%
Values	Daily Returns

MedinCell SA  vs.  Apellis Pharmaceuticals

MedinCell SA

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days MedinCell SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable essential indicators, MedinCell is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders.

Apellis Pharmaceuticals

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Apellis Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady essential indicators, Apellis Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with MedinCell and Apellis Pharmaceuticals

The main advantage of trading using opposite MedinCell and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MedinCell position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.

The idea behind MedinCell SA and Apellis Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.